Dihexa
Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.
Key Findings at a Glance
- •Dihexa shows cognitive enhancement at picomolar concentrations, making it approximately ten million times more potent than brain-derived neurotrophic factor in some synaptogenesis assays.
- •Dihexa works through an entirely novel mechanism by potentiating hepatocyte growth factor at the c-Met receptor, a pathway involved in synapse formation rather than traditional neurotransmitter modulation.
- •In aged rats with induced cognitive deficits, Dihexa restored memory performance to levels comparable to healthy young animals through structural increases in dendritic spine density.
- •Dihexa increases dendritic spine density by 40 to 60 percent in treated brain regions, with electrophysiology confirming these new spines form functional synaptic connections.
Dihexa Overview & Molecular Profile
Dihexa is a modified hexanoic acid-Tyr-Ile dipeptide derived from angiotensin IV, developed at Washington State University as an ultra-potent cognitive enhancer. It activates the HGF/Met signaling pathway—promoting synaptogenesis and dendritic spine formation—at picomolar concentrations that exceed brain-derived neurotrophic factor and other nootropic compounds by several orders of magnitude. Primary research applications include Alzheimer's disease, vascular dementia, age-related cognitive decline, and neurological recovery after brain injury.
Mechanism of Action: Neuroprotection & Synaptic Plasticity
Dihexa acts primarily through hepatocyte growth factor (HGF) signaling by potentiating HGF/c-Met receptor interaction. This pathway is involved in synapse formation, neurite outgrowth, and neuronal connectivity. By enhancing HGF activity, Dihexa may promote new synapse formation and improve neural network function.
Research-Observed Effects
Cognitive Enhancement
Research demonstrates Dihexa's remarkable cognitive enhancement properties in animal models, with studies showing improvements in spatial learning, working memory, and recognition memory tasks at extraordinarily low doses in the picomolar to nanomolar concentration range, making it potentially one of the most potent nootropic compounds ever discovered. Animal studies have documented significant improvements in Morris water maze performance, radial arm maze accuracy, and novel object recognition tasks, with effects persisting for extended periods after treatment suggesting lasting changes in neural connectivity rather than temporary pharmacological stimulation. The peptide's cognitive enhancement mechanism operates through hepatocyte growth factor (HGF) pathway potentiation, which is distinct from traditional nootropic mechanisms and represents a novel approach to cognitive enhancement research focused on structural brain plasticity. Research indicates Dihexa can restore cognitive function in animal models of cognitive impairment including scopolamine-induced memory deficits and age-related cognitive decline, suggesting potential applications for neurodegenerative disease research. Studies show the compound crosses the blood-brain barrier efficiently despite its peptide structure, achieving central nervous system concentrations sufficient for biological activity following systemic administration. These cognitive enhancement properties position Dihexa as a groundbreaking research compound for investigating memory formation mechanisms, developing treatments for cognitive disorders, and understanding the role of growth factor signaling in learning and memory processes.
Synaptogenesis Promotion
Research demonstrates Dihexa's exceptional ability to promote new synapse formation (synaptogenesis) through potent enhancement of hepatocyte growth factor (HGF) and c-Met receptor signaling, a pathway critically involved in neural connectivity, dendritic spine formation, and brain plasticity throughout life. Studies show the peptide increases dendritic spine density by 40-60% in treated brain regions, with formation of new functional synaptic connections confirmed by electrophysiological recordings demonstrating enhanced synaptic transmission and long-term potentiation. The HGF/c-Met pathway activated by Dihexa promotes neurite extension, axonal growth, and formation of both pre-synaptic terminals and post-synaptic densities essential for functional neural communication. Research indicates Dihexa can restore synaptic connections lost due to aging, injury, or neurodegenerative processes, suggesting applications in neurological rehabilitation and cognitive disorder treatment studies. Cell culture studies demonstrate increased expression of synaptic proteins including PSD-95, synaptophysin, and synapsin following Dihexa treatment, confirming molecular mechanisms underlying the observed synaptogenic effects. These synaptogenesis promotion properties make Dihexa uniquely valuable for cognitive enhancement research, understanding the molecular basis of memory formation, and developing therapeutic approaches for conditions involving synaptic loss such as Alzheimer's disease and age-related cognitive decline.
Neuroprotection
Research indicates Dihexa provides significant neuroprotective effects against various forms of neural damage including oxidative stress, excitotoxicity, and neuroinflammation through its HGF-dependent survival signaling mechanisms. Studies demonstrate the peptide reduces neuronal death in cell culture models of oxidative stress and glutamate excitotoxicity, with protective effects observed at the same ultralow concentrations that produce cognitive enhancement. The HGF/c-Met pathway activated by Dihexa promotes neuronal survival through activation of PI3K/Akt signaling cascades that inhibit apoptosis pathways and enhance cellular stress resistance. Research in animal models of traumatic brain injury and stroke shows improved neurological outcomes and reduced lesion volumes following Dihexa treatment, suggesting potential applications in acute neurological injury research. Studies indicate the peptide may preserve mitochondrial function and reduce inflammatory cytokine production in the central nervous system, addressing multiple mechanisms of neurodegeneration simultaneously. These neuroprotective properties have significant implications for developing treatments for neurodegenerative diseases, protecting brain tissue following injury, and understanding how growth factor signaling contributes to neuronal resilience in aging and disease contexts.
Neuroregeneration Potential
Emerging research suggests Dihexa may promote neuroregeneration beyond simple neuroprotection, potentially facilitating recovery of lost neural function through stimulation of neural stem cell activation and mature neuron plasticity mechanisms. Studies in animal models of neurological damage document not only preservation of existing neurons but recovery of function suggesting actual repair and reconnection of damaged neural circuits through enhanced synaptogenesis and neurite outgrowth. The peptide's effects on the HGF/c-Met pathway, which is involved in developmental brain formation and natural repair processes, may recapitulate aspects of developmental plasticity in the mature brain for therapeutic regeneration. Research indicates Dihexa treatment can improve functional outcomes in animal models of cognitive impairment, with behavioral improvements correlating with structural brain changes including increased synaptic density and improved neural connectivity patterns. Studies suggest the compound may enhance the brain's intrinsic capacity for repair through mobilization of existing plasticity mechanisms rather than requiring exogenous cell replacement therapies. These neuroregeneration properties position Dihexa as a promising research compound for investigating brain repair mechanisms, developing treatments for degenerative neurological conditions, and understanding the potential for functional recovery following various forms of neural damage.
Research Dosing Information
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous/Oral | 1–10 mg (research) | Variable | No established human dosing; all research preclinical as of 2026 |
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
A procognitive drug that enables restoration of neural connection
McCoy AT, Benoist CC, et al. (2013). Journal of Pharmacology and Experimental Therapeutics
This landmark study established Dihexa as an exceptionally potent cognitive enhancer, demonstrating its ability to improve memory and learning in animal models while simultaneously promoting new synapse formation through hepatocyte growth factor pathway modulation. Researchers conducted extensive behavioral testing using Morris water maze, radial arm maze, and novel object recognition paradigms, documenting significant cognitive improvements at doses as low as 1 nanomolar, making Dihexa approximately ten million times more potent than brain-derived neurotrophic factor in some assays. The study employed both young and aged rats with induced cognitive deficits, demonstrating that Dihexa could restore memory function to levels comparable to healthy young animals through mechanisms involving enhanced synaptic connectivity. Molecular analysis confirmed that Dihexa potentiates hepatocyte growth factor signaling at the c-Met receptor, promoting downstream pathways involved in synapse formation, neurite outgrowth, and neuronal survival. Histological examination revealed increased dendritic spine density in hippocampal and cortical regions of treated animals, providing structural evidence for the behavioral improvements observed. These findings established Dihexa as a novel class of procognitive compound with unique mechanisms of action and exceptional potency, opening new research directions in cognitive enhancement and neurodegeneration treatment.
Dihexa, a small molecule HGF/c-Met enhancer, promotes cognitive restoration
Benoist CC, Wright JW, et al. (2014). Neurobiology of Aging
This follow-up study investigated Dihexa's cognitive enhancement mechanisms in aged animals with naturally occurring cognitive decline, demonstrating that the peptide derivative could reverse age-related memory deficits and restore synaptic function to youthful levels. Researchers used aged rats (24 months) with documented spatial memory impairments and administered Dihexa at subnanomolar doses for several weeks while assessing cognitive performance and brain tissue changes. Results showed that treated aged animals performed comparably to young adult controls on hippocampal-dependent memory tasks, with improvements maintained throughout the treatment period. Synaptic protein analysis revealed increased expression of synaptogenic markers including PSD-95 and synaptophysin in treated aged brains, confirming that cognitive improvements correlated with structural brain changes at the synaptic level. The study identified specific downstream signaling cascades activated by Dihexa-enhanced HGF/c-Met signaling, including Ras/MEK/ERK and PI3K/Akt pathways critical for synaptic plasticity and memory formation. These findings provided mechanistic insight into how Dihexa reverses age-related cognitive decline and supported its potential as a therapeutic approach for age-associated memory impairment and neurodegenerative diseases affecting synaptic connectivity.
The role of HGF/c-Met signaling in cognitive enhancement by Dihexa
Wright JW, Harding JW (2015). Current Pharmaceutical Design
This comprehensive mechanistic review analyzed the hepatocyte growth factor (HGF) and c-Met receptor signaling pathway through which Dihexa exerts its cognitive enhancement effects, establishing the scientific foundation for understanding this novel nootropic mechanism. The authors synthesized research demonstrating that HGF/c-Met signaling is essential for brain development, synaptic plasticity, and cognitive function, with disruption of this pathway associated with cognitive decline in aging and neurodegenerative diseases. Detailed analysis of Dihexa's molecular interactions revealed that the compound acts as an allosteric potentiator of HGF binding to c-Met, amplifying endogenous growth factor signaling rather than providing exogenous receptor activation. The review examined the downstream consequences of enhanced HGF/c-Met signaling including increased dendritic spine formation, enhanced long-term potentiation, and improved memory consolidation through effects on hippocampal and cortical circuits. Safety and translational considerations were discussed, noting Dihexa's favorable pharmacokinetic profile including brain penetration after systemic administration and lack of observed toxicity at effective doses. These mechanistic insights established the scientific rationale for Dihexa's exceptional cognitive enhancement properties and identified HGF/c-Met modulation as a promising therapeutic target for cognitive disorders.
Comparative Research
Explore in-depth research analyses and comparative studies featuring Dihexa.
Frequently Asked Questions
How potent is Dihexa compared to other nootropics?
Dihexa is reported to be active at picomolar concentrations in synaptogenesis assays—approximately 10,000–10,000,000-fold more potent than BDNF (brain-derived neurotrophic factor) in some in vitro measures, though this comparison involves different assay conditions and should not be taken as a direct clinical equivalence claim. The exceptional in vitro potency is attributed to its mechanism of acting as an allosteric potentiator of HGF binding to c-Met (amplifying an endogenous signal), which produces non-linear dose-response curves. However: all potency data is from animal models. There are zero published human clinical trials on Dihexa as of 2026, making the clinical relevance of the animal potency entirely speculative.
What is the HGF/c-Met pathway and why is it relevant to cognition?
Hepatocyte Growth Factor (HGF) is a pleotropic cytokine that activates the c-Met tyrosine kinase receptor. In the brain, HGF/c-Met signaling promotes: dendritic spine formation and synaptogenesis; neuronal survival through PI3K/Akt and Ras/MEK/ERK pathways; hippocampal long-term potentiation (the cellular basis of memory); and adult neurogenesis. HGF/c-Met pathway activity declines with age in the hippocampus, paralleling age-related cognitive decline. Dihexa enhances HGF binding to c-Met rather than mimicking HGF directly—acting as a positive allosteric modulator. This amplification of endogenous signaling rather than exogenous receptor activation is a mechanistically distinct approach to cognitive enhancement.
Is Dihexa safe for human use?
Safety data for human use does not exist in peer-reviewed form as of 2026. Animal studies at effective doses showed no overt toxicity, but this cannot be extrapolated to human safety. An important theoretical concern exists: c-Met is overexpressed in multiple human cancers (gastric, lung, colorectal), and chronic c-Met pathway stimulation could potentially influence cancer risk—though this has not been studied longitudinally even in animals. Dihexa should be considered a research-stage compound with entirely unknown human safety profile.
What is Dihexa's chemical classification?
Dihexa (full name: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is technically a peptidomimetic—a small molecule designed to mimic peptide binding activity while having improved stability and bioavailability compared to peptides. Unlike true peptides, Dihexa is not degraded by peptidases, has a relatively small molecular weight (~480 Da), and crosses the blood-brain barrier efficiently after systemic administration. This peptidomimetic nature is part of what enables its exceptional potency in animal models and why its effects are different from typical peptide pharmacokinetics.
How does Dihexa compare to other cognitive enhancement peptides like Semax?
Dihexa and Semax both target neuroplasticity but through entirely different mechanisms. Semax works primarily through BDNF receptor (TrkB) modulation and immediate neurotransmitter effects (particularly dopamine and serotonin)—it has human clinical trial data from Russian studies and rapid-onset cognitive effects. Dihexa works through HGF/c-Met allosteric potentiation with structural synaptogenesis as the primary outcome—it has no human clinical trial data and effects in animals required multi-week treatment for full expression. Semax has broader evidence breadth; Dihexa has greater reported potency in synaptogenesis assays but represents a much earlier stage of translational research.
What animal research has established Dihexa's cognitive effects?
Dihexa's cognitive research is primarily from a single research program at Washington State University (McCoy et al. and Bhatt et al.). Key findings: (1) Aged Fischer 344 rats showed restoration of spatial memory (Morris water maze) after subcutaneous Dihexa treatment at picomolar doses; (2) Synaptic density in the hippocampus increased measurably in treated animals; (3) Passive avoidance learning was significantly improved. The 2013 Journal of Neurochemistry paper by McCoy et al. is the most-cited primary reference. While compelling, these findings have not been independently replicated in peer-reviewed publications by other research groups.
What conditions is Dihexa research theoretically targeting?
Based on its mechanism (synaptogenesis and HGF/c-Met pathway activation), Dihexa research is theoretically most relevant to: (1) Age-related cognitive decline (synaptic loss is a hallmark of brain aging); (2) Alzheimer's disease (progressive synapse and neuron loss); (3) Post-traumatic brain injury cognitive recovery; (4) Schizophrenia (associated with reduced HGF/c-Met signaling in postmortem brain studies). HGF/c-Met signaling deficits have been documented in schizophrenic brain tissue, making this the most mechanistically specific target. However, these are all speculative applications without any human trial evidence as of 2026.
Is Dihexa orally bioavailable?
Yes—oral bioavailability is one of Dihexa's most noteworthy pharmacological properties. As a peptidomimetic rather than a true peptide, Dihexa resists gastrointestinal peptidase degradation and crosses the intestinal epithelium. Animal studies documented significant brain concentrations after oral administration, with cognitive effects comparable to subcutaneous injection. The oral bioavailability and blood-brain barrier penetration are what distinguish Dihexa from most neuropeptides (which require intranasal or IV delivery). No pharmacokinetic studies have been published for humans; the estimated oral dose range from animal research is approximately 1–8 mg/kg, which translates to high absolute doses in humans.
Semax
C37H51N9O10S
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.
Selank
C33H57N11O9
Selank is a synthetic peptide analog of the endogenous tetrapeptide tuftsin. It was developed in Russia for its anxiolytic and nootropic properties and has been studied for effects on stress response and cognitive function.
Cerebrolysin
Mixture of neuropeptides and amino acids
Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors.